E-viri
Recenzirano
Odprti dostop
-
Steinman, Lawrence; Fox, Edward; Hartung, Hans-Peter; Alvarez, Enrique; Qian, Peiqing; Wray, Sibyl; Robertson, Derrick; Huang, DeRen; Selmaj, Krzysztof; Wynn, Daniel; Cutter, Gary; Mok, Koby; Hsu, Yanzhi; Xu, Yihuan; Weiss, Michael S.; Bosco, Jenna A.; Power, Sean A.; Lee, Lily; Miskin, Hari P.; Cree, Bruce A.C.
The New England journal of medicine, 08/2022, Letnik: 387, Številka: 8Journal Article
In two parallel randomized trials in patients with MS, ublituximab resulted in lower relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not affect disability.
